The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias

Vincenza Leone, Angelo Ferraro, Filippo Schepis, Antonella Federico, Romina Sepe, Claudio Arra, Concetta Langella, Giuseppe Palma, Carlo De Lorenzo, Giancarlo Troncone, Valeria Masciullo, Giovanni Scambia, Alfredo Fusco, Pierlorenzo Pallante

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We have previously reported that the expression of the CL2/CCDC80 gene is downregulated in human papillary thyroid carcinomas, particularly in follicular variants. We have also reported that the restoration of CL2/CCDC80 expression reverted the malignant phenotype of thyroid carcinoma cell lines and that CL2/CCDC80 positively regulated E-cadherin expression, an ability that likely accounts for the role of the CL2/CCDC80 gene in thyroid cancer progression. In order to validate the tumour suppressor role of the CL2/CCDC80 gene in thyroid carcinogenesis we generated cl2/ccdc80 knock-out mice. We found that embryonic fibroblasts from cl2/ccdc80-/- mice showed higher proliferation rate and lower susceptibility to apoptosis. Furthermore, cl2/ccdc80-/- mice developed thyroid adenomas and ovarian carcinomas. Finally, ret/PTC1 transgenic mice crossed with the cl2/ccdc80 knock-out mice developed more aggressive thyroid carcinomas compared with those observed in the single ret/PTC1 transgenic mice. Together, these results indicate CL2/CCDC80 as a putative tumour suppressor gene in human thyroid carcinogenesis.

Original languageEnglish
Pages (from-to)535-541
Number of pages7
JournalCancer Letters
Volume357
Issue number2
DOIs
Publication statusPublished - Feb 28 2015

Fingerprint

Thyroid Neoplasms
Thyroid Gland
Knockout Mice
Transgenic Mice
Neoplasms
Carcinogenesis
Genes
Cadherins
Tumor Suppressor Genes
Down-Regulation
Fibroblasts
Apoptosis
Carcinoma
Phenotype
Cell Line

Keywords

  • Carcinoma
  • Cl2/dro1/ccdc80
  • Knock-out mice
  • Ovary
  • Thyroid

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Leone, V., Ferraro, A., Schepis, F., Federico, A., Sepe, R., Arra, C., ... Pallante, P. (2015). The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. Cancer Letters, 357(2), 535-541. https://doi.org/10.1016/j.canlet.2014.12.010

The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. / Leone, Vincenza; Ferraro, Angelo; Schepis, Filippo; Federico, Antonella; Sepe, Romina; Arra, Claudio; Langella, Concetta; Palma, Giuseppe; De Lorenzo, Carlo; Troncone, Giancarlo; Masciullo, Valeria; Scambia, Giovanni; Fusco, Alfredo; Pallante, Pierlorenzo.

In: Cancer Letters, Vol. 357, No. 2, 28.02.2015, p. 535-541.

Research output: Contribution to journalArticle

Leone, V, Ferraro, A, Schepis, F, Federico, A, Sepe, R, Arra, C, Langella, C, Palma, G, De Lorenzo, C, Troncone, G, Masciullo, V, Scambia, G, Fusco, A & Pallante, P 2015, 'The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias', Cancer Letters, vol. 357, no. 2, pp. 535-541. https://doi.org/10.1016/j.canlet.2014.12.010
Leone, Vincenza ; Ferraro, Angelo ; Schepis, Filippo ; Federico, Antonella ; Sepe, Romina ; Arra, Claudio ; Langella, Concetta ; Palma, Giuseppe ; De Lorenzo, Carlo ; Troncone, Giancarlo ; Masciullo, Valeria ; Scambia, Giovanni ; Fusco, Alfredo ; Pallante, Pierlorenzo. / The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias. In: Cancer Letters. 2015 ; Vol. 357, No. 2. pp. 535-541.
@article{64bc2db66a6e47478d5b0bd2f441f6e5,
title = "The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias",
abstract = "We have previously reported that the expression of the CL2/CCDC80 gene is downregulated in human papillary thyroid carcinomas, particularly in follicular variants. We have also reported that the restoration of CL2/CCDC80 expression reverted the malignant phenotype of thyroid carcinoma cell lines and that CL2/CCDC80 positively regulated E-cadherin expression, an ability that likely accounts for the role of the CL2/CCDC80 gene in thyroid cancer progression. In order to validate the tumour suppressor role of the CL2/CCDC80 gene in thyroid carcinogenesis we generated cl2/ccdc80 knock-out mice. We found that embryonic fibroblasts from cl2/ccdc80-/- mice showed higher proliferation rate and lower susceptibility to apoptosis. Furthermore, cl2/ccdc80-/- mice developed thyroid adenomas and ovarian carcinomas. Finally, ret/PTC1 transgenic mice crossed with the cl2/ccdc80 knock-out mice developed more aggressive thyroid carcinomas compared with those observed in the single ret/PTC1 transgenic mice. Together, these results indicate CL2/CCDC80 as a putative tumour suppressor gene in human thyroid carcinogenesis.",
keywords = "Carcinoma, Cl2/dro1/ccdc80, Knock-out mice, Ovary, Thyroid",
author = "Vincenza Leone and Angelo Ferraro and Filippo Schepis and Antonella Federico and Romina Sepe and Claudio Arra and Concetta Langella and Giuseppe Palma and {De Lorenzo}, Carlo and Giancarlo Troncone and Valeria Masciullo and Giovanni Scambia and Alfredo Fusco and Pierlorenzo Pallante",
year = "2015",
month = "2",
day = "28",
doi = "10.1016/j.canlet.2014.12.010",
language = "English",
volume = "357",
pages = "535--541",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias

AU - Leone, Vincenza

AU - Ferraro, Angelo

AU - Schepis, Filippo

AU - Federico, Antonella

AU - Sepe, Romina

AU - Arra, Claudio

AU - Langella, Concetta

AU - Palma, Giuseppe

AU - De Lorenzo, Carlo

AU - Troncone, Giancarlo

AU - Masciullo, Valeria

AU - Scambia, Giovanni

AU - Fusco, Alfredo

AU - Pallante, Pierlorenzo

PY - 2015/2/28

Y1 - 2015/2/28

N2 - We have previously reported that the expression of the CL2/CCDC80 gene is downregulated in human papillary thyroid carcinomas, particularly in follicular variants. We have also reported that the restoration of CL2/CCDC80 expression reverted the malignant phenotype of thyroid carcinoma cell lines and that CL2/CCDC80 positively regulated E-cadherin expression, an ability that likely accounts for the role of the CL2/CCDC80 gene in thyroid cancer progression. In order to validate the tumour suppressor role of the CL2/CCDC80 gene in thyroid carcinogenesis we generated cl2/ccdc80 knock-out mice. We found that embryonic fibroblasts from cl2/ccdc80-/- mice showed higher proliferation rate and lower susceptibility to apoptosis. Furthermore, cl2/ccdc80-/- mice developed thyroid adenomas and ovarian carcinomas. Finally, ret/PTC1 transgenic mice crossed with the cl2/ccdc80 knock-out mice developed more aggressive thyroid carcinomas compared with those observed in the single ret/PTC1 transgenic mice. Together, these results indicate CL2/CCDC80 as a putative tumour suppressor gene in human thyroid carcinogenesis.

AB - We have previously reported that the expression of the CL2/CCDC80 gene is downregulated in human papillary thyroid carcinomas, particularly in follicular variants. We have also reported that the restoration of CL2/CCDC80 expression reverted the malignant phenotype of thyroid carcinoma cell lines and that CL2/CCDC80 positively regulated E-cadherin expression, an ability that likely accounts for the role of the CL2/CCDC80 gene in thyroid cancer progression. In order to validate the tumour suppressor role of the CL2/CCDC80 gene in thyroid carcinogenesis we generated cl2/ccdc80 knock-out mice. We found that embryonic fibroblasts from cl2/ccdc80-/- mice showed higher proliferation rate and lower susceptibility to apoptosis. Furthermore, cl2/ccdc80-/- mice developed thyroid adenomas and ovarian carcinomas. Finally, ret/PTC1 transgenic mice crossed with the cl2/ccdc80 knock-out mice developed more aggressive thyroid carcinomas compared with those observed in the single ret/PTC1 transgenic mice. Together, these results indicate CL2/CCDC80 as a putative tumour suppressor gene in human thyroid carcinogenesis.

KW - Carcinoma

KW - Cl2/dro1/ccdc80

KW - Knock-out mice

KW - Ovary

KW - Thyroid

UR - http://www.scopus.com/inward/record.url?scp=84920747652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920747652&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2014.12.010

DO - 10.1016/j.canlet.2014.12.010

M3 - Article

VL - 357

SP - 535

EP - 541

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -